All studies
AuthorisedTherapeutic exploratory (Phase II)Interventional

A Phase 2, Multicenter, Randomized, Parallel Treatment Arms, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CP-012B in Participants with Parkinson’s Disease with Early Morning OFF Episodes

Many people with Parkinson’s disease experience difficult early morning "OFF" periods. This occurs when medication wears off overnight, leaving people stiff, slow, or stuck when they wake up, before their first morning dose can take effect. This Phase 2 trial is evaluating whether an experimental medicine named CP-012B helps people wake up in an "ON" state, where movement is easier and smoother. Participants will be randomly assigned to take either CP-012B or a placebo (a dummy treatment with no active drug) for about six weeks (43 days). Participants will record how they feel and move each morning using a simple electronic diary. The trial aims to find out if CP-012B is safe and if it helps people start their day with better mobility and independence.

At a glance

Status
Authorised
Phase
Therapeutic exploratory (Phase II)
Sponsor
Contera Pharma A/S
Enrolment target
68
Start
05 Nov 2026

What is this study about?

Living with Parkinson’s disease often involves balancing times when medication works well (known as "ON" time) and times when symptoms return (known as "OFF" time). For many individuals, mornings are the hardest part of the day. Overnight, Parkinson’s medications gradually leave the body. As a result, people often wake up feeling stiff, slow, and unable to move easily until their first morning dose of levodopa kicks in.

This clinical study is evaluating an investigational medicine called CP-012B. Researchers want to find out whether taking CP-012B can help prevent these early morning slumps. The goal is to help participants wake up already in an "ON" state, allowing them to get out of bed and start their daily routines with greater comfort and confidence.

The trial is "double-blind" and "placebo-controlled". This means half of the participants will receive the active study medicine, while the other half will receive a matching placebo that contains no active ingredients. Neither the participants nor their study doctors will know who receives which treatment until the trial is complete. This helps ensure the results are completely fair and unbiased.

Over the course of around six weeks, participants will track their morning symptoms using an electronic diary. By comparing the results of those taking CP-012B with those taking the placebo, doctors hope to learn if this new medicine could become a valuable addition to future Parkinson’s care.

Key takeaways

  • Tests whether CP-012B helps Parkinson’s patients wake up moving well before taking morning medicine.
  • Compares the study drug directly against a dummy pill (placebo) over 43 days.
  • Open to adults aged 18 and over who regularly struggle with morning stiffness or slowness.
  • Involves recording morning symptoms on a provided electronic diary.
  • Participation is entirely voluntary and you can withdraw at any time without affecting your NHS care.

Who may be eligible?

This trial is open to adults of any age (18 years and older) who have been diagnosed with Parkinson’s disease and regularly experience early morning "OFF" episodes.

To qualify, you must regularly wake up experiencing stiffness, slow movement, or other Parkinson's symptoms before taking your first morning dose of medication. You should also be willing and able to use a handheld electronic diary to record your symptoms each morning.

Certain medical conditions or current treatments may make someone unsuitable for the study. The study medical team will review your full medical history, current Parkinson’s medicines, and overall health to confirm if this trial is safe and appropriate for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have a confirmed diagnosis of Parkinson’s disease.
  3. I regularly experience stiffness or slowness upon waking before my morning medication.
  4. I take a levodopa-containing medication as my first daily Parkinson's treatment.
  5. I am willing and able to complete a brief electronic diary entry each morning.
Answer every question to see your result.

What does participation involve?

Taking part in the trial lasts around six to eight weeks in total, including a 43-day treatment period. During the study, you will take either the study drug (CP-012B) or a matching dummy pill (placebo) as instructed by the clinical team.

You will be given an easy-to-use electronic diary (eDiary). You will use this each morning to record whether you wake up in an "ON" or "OFF" state and how long it takes for your morning movement to improve. You will complete these records during specific weeks, especially in the week before starting treatment and the final two weeks of the study.

You will visit the trial clinic several times for health check-ups. These visits will include standard physical assessments, reviews of your symptoms, blood pressure checks, and conversations about how you are feeling. The trial team will closely monitor your well-being throughout.

Potential risks and benefits

A potential benefit of joining this study is that CP-012B may improve your morning mobility and reduce your time spent feeling stiff or slow upon waking. You will also receive careful, regular health monitoring from Parkinson’s specialists. However, there is no guarantee you will personally benefit, especially since you might receive a placebo. Like any experimental medicine, CP-012B may cause unexpected side effects or discomfort. Taking part is completely voluntary. You can choose to leave the study at any time, for any reason, and your standard NHS medical care will not be affected.

Locations (3)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Poland
  • —
    Unverified
    Italy
  • —
    Unverified
    Spain

Common questions

What does waking up 'OFF' mean?

Waking up 'OFF' means your Parkinson’s symptoms, such as stiffness, tremor, or slowness, have returned overnight because your previous evening's medication has worn off. It can make getting out of bed difficult until your first morning dose starts working.

What is a placebo and why is it used?

A placebo looks identical to the real study drug but contains no active medicine. It allows researchers to compare results to see if any improvements or side effects are truly caused by CP-012B.

Can I continue taking my regular Parkinson’s medications?

In most cases, yes. The study looks at how you feel before your first morning levodopa dose. The study team will clearly explain how CP-012B fits around your standard daily medications.

What is an electronic diary (eDiary)?

An eDiary is a simple digital device, like a smartphone or tablet, provided to you by the trial team. It prompts you to answer quick, simple questions each morning about how you are moving.

Does participating cost anything?

No. The study medication, clinic visits, and health tests are provided free of charge. Many trials also help cover reasonable travel expenses to and from the clinic.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.